Literature DB >> 7257136

Epidemiological features of feline mammary carcinoma.

H M Hayes, K L Milne, C P Mandell.   

Abstract

An epidemiological survey involving 132 cats with mammary neoplasia, seen at 15 North American veterinary medical teaching hospitals, was conducted. The ratio of malignant to benign tumours was 9:1. There were 113 cases of carcinomas of all types (including two males), with adenocarcinoma being the predominant cell-type. Relative risk analysis indicated that the Siamese breed had twice the risk (P less than 0.01) of developing mammary carcinoma compared to all breeds combined. The age at diagnosis in Siamese females tended to be younger than in other breeds. Comparison of clinical and pathological features of breast cancer suggests that the cat is an appropriate surrogate for the experimental study of human breast cancer. The apparent lack of oestrogen dependency in feline breast cancer also suggests that the cat may be especially suited for evaluating therapeutic regimens for breast cancers that do not respond to hormonal manipulation.

Entities:  

Mesh:

Year:  1981        PMID: 7257136     DOI: 10.1136/vr.108.22.476

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  15 in total

1.  Feline mammary carcinoma: a retrospective evaluation of 17 cases.

Authors:  M J Tomlinson; L Barteaux; L E Ferns; E Angelopoulos
Journal:  Can Vet J       Date:  1984-12       Impact factor: 1.008

2.  Feline mammary adenocarcinoma: tumor size as a prognostic indicator.

Authors:  Jodi R Viste; Sherry L Myers; Baljit Singh; Elemir Simko
Journal:  Can Vet J       Date:  2002-01       Impact factor: 1.008

Review 3.  Infection and cancer in multicellular organisms.

Authors:  Paul W Ewald; Holly A Swain Ewald
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

4.  Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate.

Authors:  P M Martin; M Cotard; J P Mialot; F André; J P Raynaud
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Feline Mammary Cancer.

Authors:  B B Hassan; S M Elshafae; W Supsavhad; J K Simmons; W P Dirksen; S M Sokkar; T J Rosol
Journal:  Vet Pathol       Date:  2016-07-11       Impact factor: 2.221

6.  Improving the diagnosis, treatment, and biology patterns of feline mammary intraepithelial lesions: a potential model for human breast masses with evidence from epidemiologic and cytohistopathologic studies.

Authors:  Javad Yaghoobi Yeganeh Manesh; Radmehr Shafiee; Behnam Pedram; Hamed Zamankhan Malayeri; Sheida Mohajer; Sharareh Ahmadi; Shirin Ahmadi; Javad Javanbakht; Aram Mokarizadeh; Farshid Khadivar
Journal:  Tumour Biol       Date:  2014-08-21

7.  Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.

Authors:  David A Wiese; Tuddow Thaiwong; Vilma Yuzbasiyan-Gurkan; Matti Kiupel
Journal:  BMC Cancer       Date:  2013-09-03       Impact factor: 4.430

Review 8.  Cats, Cancer and Comparative Oncology.

Authors:  Claire M Cannon
Journal:  Vet Sci       Date:  2015-06-30

9.  Comparative value of clinical, cytological, and histopathological features in feline mammary gland tumors; an experimental model for the study of human breast cancer.

Authors:  Radmehr Shafiee; Javad Javanbakht; Nahid Atyabi; Alimohammad Bahrami; Danial Kheradmand; Reyhaneh Safaei; Farshid Khadivar; Ehsan Hosseini
Journal:  Diagn Pathol       Date:  2013-08-13       Impact factor: 2.644

10.  Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

Authors:  Marion Adelfinger; Ivaylo Gentschev; Julio Grimm de Guibert; Stephanie Weibel; Johanna Langbein-Laugwitz; Barbara Härtl; Hugo Murua Escobar; Ingo Nolte; Nanhai G Chen; Richard J Aguilar; Yong A Yu; Qian Zhang; Alexa Frentzen; Aladar A Szalay
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.